baber/WOPTO huggingface dataset:
Patent NZ-239680-A (NZ)
Title: Production of egg yolk with reduced cholesterol
Inventor: CULLY JAN
IPC: A23L15/00
Filed: 1991-09-05
Abstract: To prepare low-cholesterol egg yolk, the egg yolk is diluted by addition of water or an aqueous salt solution, cholesterol and cholesterol esters, which are present in the diluted egg yolk, are selectively complexed with  beta -cyclodextrin, the  beta -cyclodextrin charged with cholesterol and/or cholesterol esters is separated off from the diluted egg yolk, the added water is removed from the egg yolk, residual amounts of  beta -cyclodextrin present in the egg yolk are degraded enzymatically with the aid of  alpha -amylase and/or CTGase, the  beta -cyclodextrin is recovered from the beta -cyclodextrin complexes by treatment with water and/or an alcohol and, if required, is reused for complexing cholesterol and cholesterol esters.
Patent NZ-244517-A (NZ)
Title: Controlled release pharmaceutical preparations buoyant in gastric juices; preparation contains ph-dependent salt of polyuronic acid and hydrocolloid gelling agent and is free of ca++
Inventor: DENNIS ANDREW
IPC: A61K9/00
Filed: 1992-09-28
Abstract: A buoyant controlled release pharmaceutical powder formulation is provided which may be filled into capsules and releases a pharmaceutical of a basic character at a controlled rate regardless of the pH of the environment, which formulation includes a basic pharmaceutical, up to about 45% by weight of a pH dependent polymer which is a salt of alginic acid, such as sodium alginate, up to about 35% by weight of a pH-independent hydrocarbon gelling agent having a viscosity of up to about 100,000 centipoises in 2% solution at 20 DEG C and excipients.
Patent NZ-246823-A (NZ)
Title: 2-[1-(2-phenylalkoxyphenoxy)phenylalkyl]imidazoline derivatives; medicaments
Inventor: FREEDMAN JULES
IPC: C07D/
Filed: 1993-01-12
Abstract: The present invention is directed to a new class of arylalkoxyphenoxy-imidazoline compounds and their use for the treatment of depression, anxiety, hypertension, and migraine headaches.
Patent NZ-274498-A (NZ)
Title: Production of fatty alcohols from vegetable oils by hydrolysis/transesterification, hydrogenation and distillation
Inventor: KOHLER MICHAEL
IPC: C07C33/025
Filed: 1994-10-12
Abstract: PCT No. PCT/EP94/03348 Sec. 371 Date May 9, 1996 Sec. 102(e) Date May 9, 1996 PCT Filed Oct. 12, 1994 PCT Pub. No. WO95/11210 PCT Pub. Date Apr. 27, 1995Fatty alcohols of the formula I R1OH (I) wherein R1 is a saturated or unsaturated, linear or branched aliphatic radical having from about 8 to about 22 carbon atoms are made by an improvement in the process which comprises hydrogenating a fatty acid, a fatty acid methyl ester or a combination thereof to form a fatty alcohol. The improvement comprises removing a head fraction from the fatty acid, the fatty acid methyl ester or the fatty alcohol in such a quantity that the fatty alcohol has an iodine value of from about 20 to about 110 and less than about 4.5% by weight of conjugated compounds.
Patent NZ-295303-A (NZ)
Title: Sunscreen composition comprising a sunscreen agent, an anti-inflammatory agent and a composition for healing wounds
Inventor: MARTIN ALAIN
IPC: A61K35/35
Filed: 1995-10-05
Abstract: The present invention pertains to therapeutic sunscreen-wound healing compositions useful to minimize and treat sunburn damage. The compositions comprise a therapeutically effective amount of (1) a sunscreen agent; (2) an anti-inflammatory; and, (3) a wound healing composition. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an antioxidant; and (c) a mixture of saturated and unsaturated fatty acids. The therapeutic sunscreen-wound healing compositions may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the therapeutic sunscreen-wound healing compositions and the pharmaceutical products in which the therapeutic compositions may be used.
Patent NZ-313654-A (NZ)
Title: Cyclo-oxygenase inhibitor and amidine derivative salts, preparation method therefor, use thereof as drugs, and pharmaceutical compositions containing said salts
Inventor: CHABRIER DE LASSAUNIERE PIERRE
IPC: A61K31/19
Filed: 1996-07-15
Abstract: PCT No. PCT/FR96/01095 Sec. 371 Date Jan. 6, 1998 Sec. 102(e) Date Jan. 6, 1998 PCT Filed Jul. 15, 1996 PCT Pub. No. WO97/03678 PCT Pub. Date Feb. 6, 1997Cyclo-oxygenase inhibitor and amidine derivative salts, preparation methods therefor, pharmaceutical compositions containing said salts and the use thereof particularly as NO synthase and cyclo-oxygenase inhibitors, are disclosed.
Patent NZ-319377-A (NZ)
Title: polypeptides comprising a portion of a soluble M tuberculosis antigen
Inventor: REED STEVEN G
IPC: C12Q1/68
Filed: 1996-08-30
Abstract: olypeptides that contain at least one immunogenic portion of a soluble M. tuberculosis antigen having an N terminal sequence as defined in the specification are claimed. Also claimed are the DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against M. tuberculosis infection, or may be used for the diagnosis of tuberculosis.
Patent NZ-329739-A (NZ)
Title: Cellular communication method using partial echo values during arq mode transmission
Inventor: DIACHINA JOHN WALTER
IPC: H04L12/28
Filed: 1994-11-01
Abstract: [A method for determining ownership of ARQ Mode BEGIN and CONTINUE frames includes receiving, at a remote station, an ARQ Mode BEGIN frame with an identifier associated with the remote station.  A partial echo and transaction identifier contained in the ARQ Mode BEGIN frame is then stored.  The remote station then receives at least one subsequent ARQ Mode CONTINUE frame having partial echo and transaction identifier values that match the stored values.   The partial echo value may be assigned to a remote station within an ARQ mode BEGIN frame.  Frames containing the partial echo value are transmitted for the duration of the ARQ mode transaction.  Subsequent partial echo values match an assigned partial echo value if the subsequent partial echo values differ from the assigned partial echo value by up to a predetermined number of bits.
Patent NZ-334924-A (NZ)
Title: Paint and stain remover comprising liquid solvents absorbed in an abrasive substrate
Inventor: ROSE EDWARD S
IPC: C11D3/43
Filed: 1997-09-22
Abstract: A paint and stain remover article comprises a substrate capable of absorbing and retaining a fluid with two opposed surfaces wherein at least one surface is abrasive, and a nonabrasive liquid formulation for removing paint, stains and other marks absorbed in the substrate.  The liquid formulation comprises an aliphatic solvent, a terpene, a glycol ether or dibasic ester, and a ketone or acetate.  Initial removal action is achieved by the liquid formulation and final removal action is achieved by the abrasive surface of the substrate and by the absorption of the dissolved marking residue into the substrate.  The substrate may comprise a cloth-like towel and a plurality of such towels may be provided in a continuous roll, a line of perforations between each towel, and housed in a selectively sealable, essentially airtight container.
Patent NZ-334992-A (NZ)
Title: Meningococcus vaccine comprising the valence of BZ83 strain
Inventor: QUENTIN-MILLET MARIE-JOSE
IPC: A61P25/00
Filed: 1998-08-03
Abstract: A pharmaceutical composition comprising the subunit of least molecular weight (TbpB) of the human transferrin receptor (HTR) of a Neisseria meningitis strain (eg: the BZ83 strain). The strain has a DNA sequence coding for Tbp which contains two AvaII restriction sites, 3 HincII restriction sites, no VspI restriction site and no XhoI restriction site.
Patent NZ-502186-A (NZ)
Title: Encapsulation of hazardous waste materials in a settable composition
Inventor: RECHICHI DINO
IPC: B09B3/00
Filed: 1998-05-29
Abstract: Hazardous waste materials including heavy metals such as arsenic, mercury, nickel and chromium residues, as well as radioactive materials are added to a settable cement composition comprising calcium carbonate and a caustic magnesium oxide.  A slurry is formed and this is allowed to set to encapsulate the waste material. None of the hazardous waste material is leached out of the set composition.
Patent NZ-502245-A (NZ)
Title: Ink-jet printable microporous film
Inventor: WALLER CLINTON P
IPC: C08J9/26
Filed: 1998-07-08
Abstract: Ink-jet receptor media are disclosed that have both a fluid management system and a pigment management system for use with pigmented ink-jet inks that produce vibrant, durable images. The fluid management system is provided by microporous media with the presence of surfactants, if needed. The pigment management system is provided by either fluorinated silica particles or inorganic multivalent metal salts impregnated into pores of the microporous media.
Patent NZ-502753-A (NZ)
Title: Production of a biodegradable product with a starting material comprising amylose in flour derived from an edible crop plant, wood flour, a natural wax and water
Inventor: MEEUWSEN MARINUS CORNELIS
IPC: C08L3/02
Filed: 1998-07-08
Abstract: A means of producing a biodegradable product, which is intended for temporary storage of foodstuffs, is described.  This product may be used in the manufacture of objects such as containers for hot and cold foodstuffs or liquids.  The product is made under conditions of pressure and heat in a mould, from a basic material containing amylose, wood flour, natural wax and water. The method of manufacture is characterised in the composition of the basic material: a moist granulate comprising 50 - 250 parts by weight amylose - comprising flour derived from an edible crop plant; 10 - 85 parts by weight wood flour; 2 - 30 parts by weight natural wax and 50 - 250 parts by weight water.
Patent NZ-503568-A (NZ)
Title: Biphasic lipid vesicle composition for transdermal administration of an immunogen
Inventor: FOLDVARI MARIANNA
IPC: A61K9/127
Filed: 1998-08-28
Abstract: A composition for transdermal administration of an immunogen comprising an immunogen entrapped in lipid vesicles having an oil-in-water emulsion in the central core compartment. The vesicles are administered transdermally to elicit an immune response in a subject.
Patent NZ-504494-A (NZ)
Title: A wind power plant
Inventor: LEIJON MATS
IPC: F03D9/00
Filed: 1998-11-30
Abstract: The magnetic circuit of a generator in a wind power plant is arranged to directly supply a high supply voltage of 2 - 50 kV, preferably higher than 10 kV.  The generator is provided with solid insulation and its winding includes a cable comprising one or more current-carrying conductors with a number of strands surrounded by at least one outer and one inner semiconducting layer and intermediate insulating layers.  The outer semiconducting layer is at earth potential   The stator winding may be produced with full or fractional slot winding, the phases of the winding being Y-connected.  The Y-point may be insulated and protected from over-voltage by means of surge arresters, or else the Y-point may be earthed via a suppression filter.  Also described is a wind power plant, a generator included in the plant and a variable speed system for such a plant.
Patent NZ-505144-A (NZ)
Title: Acoustic device comprising a panel member relying on bending wave action
Inventor: DJAHANSOUZI BIJAN
IPC: H04R29/00
Filed: 1999-02-09
Abstract: An acoustic device relying on bending wave action in a panel member, particularly distribution of resonant modes of such bending wave action and related acoustically significant surface vibration over area of said panel member to desired or at least acceptable acoustic device performance.  The device complies with selecting parameters of the panel member affecting the distribution, including configuration/geometry and/or bending stiffness(es), and/or location(s) of bending wave transducer(s) in the area of said panel member.  The selecting being in accordance with analytical assessment of power transfer related characteristic(s) of the panel member thus the acoustic device concerned and desiderata therefor correlating with achieving the acoustic device performance.
Patent NZ-506077-A (NZ)
Title: Method for forming a moving hearth in a furnace for producing reduced iron agglomerates
Inventor: TANAKA HIDETOSHI
IPC: C21B13/10
Filed: 1999-11-01
Abstract: A moving hearth is formed by providing a layer of hearth material 4 primarily composed of iron oxide on a base refractory 3 in a reducing furnace and then sintering the hearth material so that the sintered moving hearth is not melted at an operational temperature in a reducing step. The moving hearth has high durability, and can maintain surface flatness during operation.
Patent NZ-507763-A (NZ)
Title: N-substituted aminotetralin sulphonamide derivatives useful as ligands for the neuropeptide Y Y5 receptor used in the treatment of obesity and other disorders
Inventor: DAX SCOTT L
IPC: A61P25/08
Filed: 1999-04-12
Abstract: A N-substituted aminotetralin or an enantiomer, diastereomer and pharmaceutically acceptable salt thereof has the formula (I) wherein: R1 is independently hydrogen, hydroxy, halo, optionally substituted alkoxy, cycloalkyl, cycloalkoxy, nitro, amino, alkylamino, dialkylamino, cycloalkylamino, cyano, carboxy, alkoxycarbonyl, alkylcarbonyloxy, formyl, carbamoyl or optionally substituted phenyl; n is 0 to 2 and m is 0 to 3 B1 is hydrogen or optionally substituted alkyl and B2 is hydrogen or optionally substituted alkyl; Y is methylene; R2 is hydrogen, hydroxy, alkyl, alkenyl, naphthyl, cycloalkyl, halo or optionally substituted phenyl, phenoxy, phenylthio or heteroaryl group; L is alkylene, alkenylene, alkynylene, alkylene cycloalkyIalkylene, alkenylene, alkenylene, alkynylene cycloalkylalkynylene, alkylene arylalkylene or alkenylene arylalkenylene and R3 is optionally substituted alkyl, cycloalkyl, phenyl, naphthyl or heteroaryl.  The compounds are useful for treating disorders and diseases associated with NPY receptor subtype 5 such as disorders or disease states caused by eating disorders, obesity, bulimia nervosa, diabetes, dyspilipidimia, hypertension, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual/reproductive disorders, depression, anxiety, cerebral hemorrhage, shock, congestive heart failure, nasal congestion or diarrhea.
Patent NZ-510051-A (NZ)
Title: Rotor for the treatment of molten metal extending from below furnace through stator pipe
Inventor: HEGGSETH BJARNE
IPC: F27D99/00
Filed: 2001-02-20
Abstract: The device, including a rotor, is for the treatment of a liquid such as molten metal in a reactor by supplying gas and/or particulate material to the liquid.  A rotor shaft extends up through the base of the reactor and is arranged so that it can rotate inside a stator pipe which extends up from the base of the reactor, whereby the rotor shaft and the stator pipe extend through an opening in the lower side of the rotor and into a cavity of the rotor and whereby the rotor shaft is connected to the rotor via a fixing device inside the rotor cavity, while the stator pipe ends in the cavity.
Patent NZ-511702-A (NZ)
Title: A parking management system
Inventor: HAMMOND JACK DAVID
IPC: G07B15/02
Filed: 1999-10-15
Abstract: A parking management system includes: sensing means (24) for sensing the presence of a vehicle in a parking position; a housing module (12) having: communication means (26, 83) for communicating with a network; transaction means (105, 107, 112), in communication with the communication means and accessible to a user of the system, adapted to receive payment for an overall time period in which the presence of the vehicle is sensed, and processing means (26) for monitoring the sensing means (24) and for determining the payment according to a variable fee structure, the processing means (26) being in communication with the communication means (83) and the transaction means (105, 107).
Patent NZ-512205-A (NZ)
Title: Endovascular system for the treatment of stenoses of the carotid and catheter for this system
Inventor: GARDELLI ANTONIO
IPC: A61M29/00
Filed: 1999-11-30
Abstract: A   catheter,   in   particular   for   endovascular applications,  of the kind comprising a long  and  flexible, hollow,  tubular  body  having  an  insertion  end   and   a connection end intended to remain outside the body, as  well as,  in  the insertion end, at least two elements which  are expendable/contractible by means of external  operation  and which  are located at a distance from each other such as  to be  able to operate one upstream and the other downstream of a  given  section  of a vessel, said expandable/contractible elements  being expandable and/or being able to be  expanded so   that   the  diameters  of  the  expandable/contractible elements  substantially  conform to  the  diameters  of  the vessels inside which they are intended to be positioned,  so as  to  block temporarily the circulation inside said vessel section,  characterized in that the two elements located  at the  insertion  end are inflatable/deflatable  by  means  of supply  and  discharge ducts which are each provided  wholly within  the  thickness of the same catheter  wall  from  the connection end to the first of the two elements.
Patent NZ-525304-A (NZ)
Title: A razor or cartridge and methods of forming razors or cartridges
Inventor: GARLAND COLMAN C
IPC: B26B21/44
Filed: 1999-02-12
Abstract: A razor or cartridge formed from a plurality of razor components comprising at least one razor blade and more than one shaving aid element in close proximity to one another and non-coaxially positioned on as same razor component without another razor component there between. At least one of the shaving aid elements being formed separate from the other of said shaving aid elements. (62) Divided out of 506218
Patent NZ-526511-A (NZ)
Title: Condensed purine derivatives as A1 adenosine receptor antagonists
Inventor: LIN KO-CHUNG
IPC: A61K31/52
Filed: 2001-11-30
Abstract: A compound of formula I and pharmaceutical compositions comprising a compound of formula I are disclosed. The compositions are useful for blocking A1 adenosine receptors in a patient and in treating diseases or disorders wherein activation of A1 receptors plays a causative role in the disease or disorder. These diseases or disorders may be selected form systematic hypertension, renal failure, diabetes, asthma, an edematous condition, congestive heart failure, and renal dysfunction. A process for preparing a compound of formula I is also disclosed.
Patent NZ-534434-A (NZ)
Title: Drive mechanism for power tool
Inventor: STONES KEVIN
IPC: H01H9/06
Filed: 2004-07-30
Abstract: A drive mechanism for a power tool is disclosed, in which the power tool has a housing, a motor provided in the housing, and an output shaft adapted to be caused by the motor to execute reciprocating motion. The drive mechanism comprises a gear plate (34) adapted to rotate about a first axis (Z-Z) and having a plurality of elongate first teeth (33) extending substantially in a plane perpendicular to the first axis, and connecting means cooperating with the gear plate and adapted to cause reciprocating movement of an output shaft of the tool in response to rotation of the gear plate about the first axis, wherein the reciprocating movement has a component perpendicular to the first axis. Conventional drive mechanisms which have an output shaft adapted to be caused by the motor to execute reciprocating motion generally have bevel gears with teeth formed at 45degree to the axis of rotation of the gears. By providing a gear plate and connecting means which provide a reciprocating drive force for an output shaft of a power tool with teeth formed at 90degree to the axis of rotation of the gear, instead of teeth formed at 45degree to the axis of rotation of the gear, this provides the advantage that the gear is cheaper and easier to make as the gear teeth do not have to be formed as accurately as prior art inclined gear teeth. Also, the gear plate does not need to be as accurately located relative to the gear driving it, since some longitudinal movement in the direction of the mutually engaging teeth is possible without the gears ceasing to function correctly.
Patent NZ-535435-A (NZ)
Title: Use of dispersion polymers as friction reducers in aqueous fracturing fluids
Inventor: BLAIR CECIL C
IPC: F17D1/17
Filed: 2003-04-03
Abstract: A method of reducing friction resulting from turbulent flow in an aqueous fracturing fluid in an oil field fracturing process is disclosed, wherein the method comprises adding to the aqueous fracturing fluid an effective friction-reducing amount of one or more dispersion polymers, wherein the dispersion polymer is composed of from about 5 to about 95 mole percent of one or more nonionic monomers and from about 95 to about 5 mole percent of one or more cationic or anionic monomers and has a molecular weight of at least 100,000.
Patent NZ-536472-A (NZ)
Title: Method for absorption of acid gases
Inventor: VERSTEEG GEERT FREDERIK
IPC: B01D53/77
Filed: 2003-05-07
Abstract: Disclosed is a method for absorbing acid gases from a gas mixture by contacting the gas mixture with a liquid in which is dissolved so high a concentration of an amino acid or a salt thereof that a precipitate is formed. The method is characterised in that the contact takes place in a column of the packing-free type or a column suitable for processing slurries. Preferably the amino acid is as a potassium taurate salt.
Patent NZ-537201-A (NZ)
Title: Protein extraction from canola oil seed meal
Inventor: MILANOVA RADKA
IPC: C07K1/14
Filed: 2003-06-19
Abstract: The recovery of protein from canola oil seed meal and other oil seed meals in the preparation of canola or other oil seed protein isolate is improved in comparison to conventional toasted meal by the use of a meal which has been air-desolventized at a temperature below about 50 DEG C.
Patent NZ-540664-A (NZ)
Title: Solid drug for oral use
Inventor: NAGANUMA TSUYOSHI
IPC: A61P43/00
Filed: 2003-12-11
Abstract: Disclosed is a capsule which comprises (1) a granular material containing a) as an active ingredient, a compound represented by the formula (I) (KMD-3213), b) D-mannitol; and (2) c) a lubricant selected from magnesium stearate, calcium stearate or talc, and d) sodium lauryl sulfate, wherein 85 % dissolution time is not more than 60 minutes in a dissolution test according to method 2 (paddle method) of Japanese pharmacopoeia in a condition using water as a test medium and a paddle speed of 50 rpm. A method for preparing the capsule is also disclosed, which comprises (1) granulating a compound represented by the formula (I) (KMD-3213) and b) D-mannitol by a wet granulation process; and (2) mixing the granular material obtained in step (1), c) a lubricant selected from magnesium stearate, calcium stearate or talc, and d) sodium lauryl sulfate. The capsule is for oral administration in the treatment of dysuria.